Navigation Links
A Statement from GlaxoSmithKline Consumer Healthcare on 2008 Update to the U.S. Public Health Service Guideline on Treating Tobacco Use and Dependence
Date:5/7/2008

PARSIPPANY, N.J., May 7 /PRNewswire/ -- GlaxoSmithKline (GSK) Consumer Healthcare, marketer of the leading smoking cessation products including Nicorette(R) gum, NicoDerm(R) CQ(R) patch, and Commit(R) lozenge, applauds the release of the updated 2008 U.S. Public Health Service (PHS) Guideline on Treating Tobacco Use and Dependence. Too many smokers lower their chances of quitting by relying on cold turkey approaches to become tobacco-free. The Guideline is an important validation of the need for clinicians to recommend the use of effective tobacco dependence counseling and medication. The Guideline reflects considerable progress in tobacco cessation research over the past decade to help identify the most effective strategies at reducing tobacco dependence.

We believe the 2008 update is of particular significance as it includes the addition of the Commit nicotine lozenge which can reliably increase long-term smoking abstinence. The Commit lozenge is approved by the U.S. Food and Drug Administration (FDA) to help withdrawal symptoms and cravings associated with quitting smoking, has a groundbreaking dosage selector (Time to First Cigarette) so a smoker can choose the strength that's right for them and provides low, safe doses of nicotine to ease withdrawal from cigarettes.

The updated Guideline reflects the distillation of thousands of research articles, and continues to recommend nicotine replacement products (NRT), such as Nicorette gum and NicoDerm CQ patch, as a first-line therapy for quitting, as they "increase significantly rates of long-term smoking abstinence."(1)

GlaxoSmithKline's NRT brands offer a step-down therapy to help smokers break their dependence on tobacco and safely wean off nicotine. Clinical trials have demonstrated that these brands double a smoker's chances of quitting versus placebo.(2) They are extensively proven to significantly reduce cravings and other withdrawal symptoms during quitting, allowing smokers to foc
'/>"/>

SOURCE GlaxoSmithKline Consumer Healthcare
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine news :

1. Statement by UHW President Sal Rosselli on SEIU Threat to Sue UHW Leaders
2. Pelosi Statement on Cover the Uninsured Week
3. Medarex and Bristol-Myers Squibb Joint Statement on Submission Status of Ipilimumab
4. Statement by H.E. Jakaya Mrisho Kikwete, President of the United Republic of Tanzania, and Chairman of the African Union, in Response to UN-SG Call to Action on Malaria
5. AHIP Statement on Senate Passage of the Genetic Information Nondiscrimination Act
6. SEIU RN Dian Palmer Calls on AFL-CIO Head John Sweeney to Review Video From Dearborn Protest, Retract Statement Accepting CNA Distortions
7. CNA/NNOC Statement on Restraining Order Against SEIU: Threats, Harassment and Stalking of RNs Remain Out of Bounds
8. Statement: Congress Should Include the Physician Self-Referral Provision in the Farm Bill for Patients and Communities
9. Statement From Larry Minnix, President & CEO, American Association of Homes and Services for the Aging (AAHSA) on the Senate Special Committee on Aging Hearing, Caring for Our Seniors: How Can We Support the Frontlines?
10. Statement by SEIU International President Andy Stern Regarding CNA Temporary Restraining Order
11. Statement of the American Diabetes Association Supporting Federal Courts Ruling on New York City Proposal
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2013)... features Toppik and Bosley hair fibers, two hair loss concealer ... balding hair. Hair loss treatments can be a lengthy process. ... this waiting period, one can use these hair loss concealers. ... transplant surgery in general. , Bosley and Toppik Hair ... to eliminate the appearance of balding and thinning hair. It ...
(Date:5/22/2013)... (PRWEB) May 22, 2013 Beginning Aug. ... in the Conrad Foundation’s Spirit of Innovation Challenge ... technical plan competition, free and open to students ages ... The Spirit of Innovation Challenge celebrates the life and ... walk on the Moon. The program challenges teens to ...
(Date:5/22/2013)... MD (PRWEB) May 22, 2013 According ... is an autoimmune disorder effecting up to 3 million ... causing damage to the small intestine and mal-absorption of ... such as diarrhea, constipation, weight loss and vitamin deficiency, ... diet. While there are many gluten-free foods that celiac ...
(Date:5/22/2013)... Toronto, May 22 2013 - Research presented today ... reactions in rats similar to those produced by ... results, presented by addiction expert Francesco Leri, Associate ... the University of Guelph, suggest food addiction could ... epidemic. These results were presented at the ...
(Date:5/22/2013)... (HealthDay News) -- Use of the antidepressant Lexapro ... heart condition, a new study finds. ... stress-induced myocardial ischemia." Although people with this condition ... is not receiving adequate blood supply, according to ... Durham, N.C. However, the researchers found that ...
Breaking Medicine News(10 mins):Health News:TheBeautyPlace.com Divulges Two Innovative Hair Loss Concealers on the Market Today: Bosley Hair Thickening Fibers and Toppik Hair Building Fibers 2Health News:Conrad Foundation Announces 2013-2014 Spirit of Innovation Challenge Launch Date 2Health News:During Celiac Awareness Month, Nutrition Expert Keri Glassman Encourages People with Celiac Disease to Find a Fiber Alternative like Konsyl Original Formula 2Health News:During Celiac Awareness Month, Nutrition Expert Keri Glassman Encourages People with Celiac Disease to Find a Fiber Alternative like Konsyl Original Formula 3Health News:Addiction to unhealthy foods could help explain the global obesity epidemic 2Health News:Antidepressants May Be Helpful for Some Heart Patients: Study 2Health News:Antidepressants May Be Helpful for Some Heart Patients: Study 3
... million children under the age of five and 1.7 ... sanitation, an international conference was told Saturday. // , ... utmost importance, and if we have to ensure gender ... problems need immediate attention," said Bindeshwar Pathak, founder, Sulabh ...
... discovery of neural stem cells and their potential for someday ... recent research identified “cancer stem cells,” a small population of ... a malignant brain tumor. Theoretically, if these mother cells can ... itself. On the other hand, if these cells are not ...
... A in a middle school in south China's Guangxi Zhuang ... said Friday//. ,All the students have been identified as ... suffering from symptoms of hepatitis A and 33 others are ... head of the Guangxi centre for disease control and prevention. ...
... Children’s Hospital Boston report a new and efficient strategy, ... that can be transplanted// without the risk of rejection ... system. ,Though done in mice, the work establishes ... of customized embryonic stem cells that are genetically matched ...
... under-report patient safety incidents, particularly those resulting in harm, ... authors suggest that the current system, which relies on ... is to gather accurate information on the extent of ... safety incidents are common in hospitals, and many of ...
... Scientific, technological and medical advances made in the past ... and more effective treatment options/// and better outcomes for ... the article, Shlomo Melmed, M.D., senior vice president for ... Research Institute at Cedars-Sinai, provides an update on medical ...
Cached Medicine News:Health News:Poor Sanitation Causes 3.1 Million Child Deaths In Asia 2Health News:Genes That Allow Brain Cancer-Causing Stem Cells to Resist Treatment Identified 2Health News:Genes That Allow Brain Cancer-Causing Stem Cells to Resist Treatment Identified 3Health News:Researchers Create Genetically-Matched Embryonic Stem Cells for Transplantation 2Health News:Researchers Create Genetically-Matched Embryonic Stem Cells for Transplantation 3Health News:Hospitals Miss Most Patient Safety Incidents 2Health News:Options Improving for Patients With Acromegaly and Gigantism 2Health News:Options Improving for Patients With Acromegaly and Gigantism 3
(Date:5/22/2013)... WORCESTER, Mass. and TORONTO ... www.generex.com ) (OTCBB: GNBT) today announced three presentations demonstrating ... developed by its wholly-owned subsidiary, Antigen Express, Inc. ( ... annual meeting of the American Society of Clinical Oncology ... from May 31 through June 4, 2013. ...
(Date:5/22/2013)... , 22. Mai 2013  Grifols, ... in Barcelona , Spanien, ... dass eine höhere Dosis von PROLASTIN©-C (Alpha1-Proteinasehemmer ... mit Alpha1-Antitrypsinmangel (AAT) auf ein Niveau anhebt, ... bezeichneten Bereichs liegt. ATT-Mangel ist eine lebensbedrohliche, ...
(Date:5/22/2013)... TORONTO , May 22, 2013  Medifocus, Inc. ... John Mon , Chief Operating Officer, will present at ... 30, 2013 in New York City ... presentation is scheduled to begin at 4:00 p.m. EDT and ... webcast, go to:   http://wsw.com/webcast/marcum/mfs.v/   For more ...
Breaking Medicine Technology:Generex Announces ASCO Presentations on the Antigen Express Advanced Stage AE37 Cancer Vaccine 2Generex Announces ASCO Presentations on the Antigen Express Advanced Stage AE37 Cancer Vaccine 3Generex Announces ASCO Presentations on the Antigen Express Advanced Stage AE37 Cancer Vaccine 4Studie von Grifols zeigt, dass eine höhere Dosis von PROLASTIN-C den Alpha1-PI-Spiegel in Patienten mit AAT-Mangel in den normalen Bereich anhebt 2Studie von Grifols zeigt, dass eine höhere Dosis von PROLASTIN-C den Alpha1-PI-Spiegel in Patienten mit AAT-Mangel in den normalen Bereich anhebt 3Studie von Grifols zeigt, dass eine höhere Dosis von PROLASTIN-C den Alpha1-PI-Spiegel in Patienten mit AAT-Mangel in den normalen Bereich anhebt 4Medifocus, Inc. to Present At The Second Annual Marcum LLP MicroCap Conference 2Medifocus, Inc. to Present At The Second Annual Marcum LLP MicroCap Conference 3
... Pharmaceuticals, Inc. (Nasdaq: ONXX ) today announced ... acquire Proteolix, Inc., a privately held biopharmaceutical company ... target the proteasome for the treatment of hematological ... carfilzomib, is a proteasome inhibitor currently in multiple ...
... , EXTON, Pa., Oct. 9 Kensey Nash ... release its earnings results for its first quarter ended September ... 22, 2009. , Joe Kaufmann, President and CEO, ... Thursday, October 22, 2009 at 9:00 A.M. Eastern Time. ...
Cached Medicine Technology:Onyx Pharmaceuticals to Acquire Proteolix, Inc. 2Onyx Pharmaceuticals to Acquire Proteolix, Inc. 3Onyx Pharmaceuticals to Acquire Proteolix, Inc. 4Onyx Pharmaceuticals to Acquire Proteolix, Inc. 5Kensey Nash Corporation Announces Its First Quarter Fiscal Year 2010 Earnings Release Date and Teleconference 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: